Anti-cytokine treatment for Takayasu arteritis: State of the art

Intractable and Rare Diseases Research

Volumn 3, Issue 1, 2014, Pages 29-33

  Tombetti, Enrico ^a,b   Di Chio, Maria Chiara ^a,b   Sartorelli, Silvia ^a,b   Bozzolo, Enrica ^a   Sabbadini, Maria Grazia ^a,b   Manfredi, Angelo A ^a,b   Baldissera, Elena ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Angioplasty; Surgery; Takayasu arteritis; Tocilizumab; Tumor necrosis factor (TNF)

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AORTA ARCH SYNDROME; ARTERIAL INFLAMMATION; ARTERIAL WALL REMODELLING; ARTERY DISEASE; BIOLOGICAL THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; DOPPLER ECHOGRAPHY; DRUG DOSE ESCALATION; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL;

EID: 85000225782     PISSN: 21863644     EISSN: 2186361X     Source Type: Journal    
DOI: 10.5582/irdr.3.29     Document Type: Note

References (50)

1. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007; 56:1000-1009.
2. Maksimowicz-McKinnon K, Hoffman GS. Takayasu arteritis: What is the long-term prognosis? Rheum Dis Clin North Am. 2007; 33:777-786.
3. Freitas DS, Camargo CZ, Mariz HA, Arraes AE, de Souza AW. Takayasu arteritis: Assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int. 2012; 32:703-709.
4. Cong XL, Dai SM, Feng X, Wang ZW, Lu QS, Yuan LX, Zhao XX, Zhao DB, Jing ZP. Takayasu's arteritis: Clinical features and outcomes of 125 patients in China. Clin Rheumatol. 2010; 29:973-981.
5. Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation. 1994; 90:1855-1860.
6. Lee GY, Jang SY, Ko SM, Kim EK, Lee SH, Han H, Choi SH, Kim YW, Choe YH, Kim DK. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: Analysis of 204 Korean patients at a single center. Int J Cardiol. 2012; 159:14-20.
7. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS.Takayasu arteritis. Ann Intern Med. 1994; 120:919-929.
8. Soto ME, Espinola N, Flores-Suarez LF, Reyes PA. Takayasu arteritis: Clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis. Clin Exp Rheumatol. 2008; 26(3 Suppl 49):S9-S15.
9. Mason JC. Takayasu arteritis - advances in diagnosis and management. Nat Rev Rheumatol. 2010; 6:406-415.
10. Ogino H, Matsuda H, Minatoya K, Sasaki H, Tanaka H, Matsumura Y, Ishibashi-Ueda H, Kobayashi J, Yagihara T, Kitamura S. Overview of late outcome of medical and surgical treatment for Takayasu arteritis. Circulation. 2008; 118:2738-2747.
11. Mwipatayi BP, Jeffery PC, Beningfield SJ, Matley PJ, Naidoo NG, Kalla AA, Kahn D. Takayasu arteritis: Clinical features and management: Report of 272 cases. ANZ J Surg. 2005; 75:110-117.
12. Subramanyan R, Joy J, Balakrishnan KG. Natural history of aortoarteritis (Takayasu's disease). Circulation. 1989; 80:429-437.
13. Sharma BK, Sagar S, Singh AP, Suri S. Takayasu arteritis in India. Heart Vessels Suppl. 1992; 7:37-43.
14. Park MC, Lee SW, Park YB, Chung NS, Lee SK. Clinical characteristics and outcomes of Takayasu's arteritis: Analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol. 2005; 34:284-292.
15. Hotchi M. Pathological studies on Takayasu arteritis. Heart Vessels Suppl. 1992; 7:11-17.
16. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. The New England journal of medicine. 2003; 349:160-169.
17. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009; 68:318-323.
18. Mavrogeni S, Dimitroulas T, Chatziioannou SN, Kitas G. The Role of Multimodality Imaging in the Evaluation of Takayasu Arteritis. Semin Arthritis Rheum. 2013; 42:401-412.
19. Tombetti EMA, Sabbadini MG, Baldissera E. Management options for Takayasu arteritis. Expert Opinion on Orphan Drugs. 2013; 1:685-693.
20. Arnaud L, Haroche J, Limal N, Toledano D, Gambotti L, Costedoat Chalumeau N, Le Thi Huong Boutin D, Cacoub P, Cluzel P, Koskas F, Kieffer E, Piette JC, Amoura Z. Takayasu arteritis in France: A single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine (Baltimore). 2010; 89:1-17.
21. Ishikawa K. Effects of prednisolone therapy on arterial angiographic features in Takayasu's disease. Am J Cardiol. 1991; 68:410-413.
22. Vanoli M, Daina E, Salvarani C, Sabbadini MG, Rossi C, Bacchiani G, Schieppati A, Baldissera E, Bertolini G; Itaka Study Group. Takayasu's arteritis: A study of 104 Italian patients. Arthritis Rheum. 2005; 53:100-107.
23. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford). 2006; 45:545-548.
24. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004; 50:2296-2304.
25. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: Long-term follow-up. Ann Rheum Dis. 2008; 67:1567-1569.
26. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup. Arthritis Care Res (Hoboken). 2012; 64:1079-1083.
27. Mekinian A, Neel A, Sibilia J, et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford). 2012; 51:882-886.
28. Quartuccio L, Schiavon F, Zuliani F, Carraro V, Catarsi E, Tavoni AG, Bombardieri S, Punzi L, De Vita S. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol. 2012; 30:922-928.
29. Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z, Cacoub P, Saadoun D. Anti TNF-alpha in refractory Takayasu's arteritis: Cases series and review of the literature. Autoimmun Rev. 2012; 11:678-684.
30. Nishimoto N, Kishimoto T. Interleukin 6: From bench to bedside. Nature clinical practice Rheumatology. 2006; 2:619-626.
31. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: A guide for therapeutic decisions? Circulation. 1999 Jul 6;100(1):55-60.
32. Seko Y, Sato O, Takagi A, Tada Y, Matsuo H, Yagita H, Okumura K, Yazaki Y. Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Circulation. 1996; 93:1788-1790.
33. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008; 58:1197-1200.
34. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly. 2011; 141:w13156.
35. Salvarani C, Magnani L, Catanoso MG, Pipitone N, Versari A, Dardani L, Pulsatelli L, Meliconi R, Boiardi L. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clinical and experimental rheumatology. 2012; 30(1 Suppl 70):S90-S93.
36. Bredemeier M, Rocha CM, Barbosa MV, Pitrez EH. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol. 2012; 30(1 Suppl 70):S98-S100.
37. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, Stone JR, Stone JH. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012; 64:1720-1729.
38. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, Pulsatelli L, Meliconi R, Boiardi L. Tocilizumab: A novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012; 51:151-156.
39. Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M, Fain O; Club Rhumatismes et Inflammation, and SNFMI. Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review. Autoimmun Rev. 2013; 12:1143-1149.
40. Goel R, Danda D, Kumar S, Joseph G. Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis. International journal of rheumatic diseases. 2013; 16:754-761.
41. Nakaoka Y, Higuchi K, Arita Y, et al. Tocilizumab for the treatment of patients with refractory takayasu arteritis. International heart journal. 2013; 54:405-411.
42. Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E. Treatment of Refractory Takayasu Arteritis with Tocilizumab: 7 Italian Patients from a Single Referral Center. J Rheumatol. 2013; 40:2047-2051.
43. Youngstein T, Mason JC. Interleukin 6 Targeting in Refractory Takayasu Arteritis: Serial Noninvasive Imaging is Mandatory to Monitor Efficacy. J Rheumatol. 2013; 40:1941-1944.
44. Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, Doglioni C, Manfredi AA, Baldissera E, Sabbadini MG. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med. 2011; 155:425-433.
45. Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis. ClinicalTrials.gov: NCT00556439.
46. Miyata T, Sato O, Koyama H, Shigematsu H, Tada Y. Long-term survival after surgical treatment of patients with Takayasu's arteritis. Circulation. 2003; 108:1474-1480.
47. Fields CE, Bower TC, Cooper LT, Hoskin T, Noel AA, Panneton JM, Sullivan TM, Gloviczki P, Cherry KJ Jr. Takayasu's arteritis: Operative results and influence of disease activity. J Vasc Surg. 2006; 43:64-71.
48. Saadoun D, Lambert M, Mirault T, Resche-Rigon M, Koskas F, Cluzel P, Mignot C, Schoindre Y, Chiche L, Hatron PY, Emmerich J, Cacoub P. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: A multicenter experience. Circulation. 2012; 125:813-819.
49. Pajari R, Hekali P, Harjola PT. Treatment of Takayasu's arteritis: An analysis of 29 operated patients. Thorac Cardiovasc Surg. 1986; 34:176-181.
50. Park MC, Lee SW, Park YB, Lee SK, Choi D, Shim WH. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatology (Oxford). 2006; 45:600-605.